한빛사논문
- 조회488
1Ji Soo Park,* 2Yoo Jung Cho,* 3,4Je-Yeon Yun, 5Hye Jin Lee, 6Jinho Yu, 2Hyeon-Jong Yang,† 1Dong In Suh,† on behalf of the Korean childhood Asthma REsearch team
1Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
2Department of Pediatrics, Pediatric Allergy and Respiratory Center, Soonchunhyang University College of Medicine, Seoul, Korea
3Seoul National University Hospital, Seoul, Republic of Korea
4Yeongeon Student Support Center, Seoul National University College of Medicine, Seoul, Republic of Korea
5Department of Pediatrics, Catholic University College of Medicine, Seoul, Korea
6Department of Pediatrics, Ulsan University Asan Medical Center, Seoul, Korea
* These authors contributed equally as co-first authors.
† These authors contributed equally as co-corresponding authors.
Co-Corresponding authors: Hyeon-Jong Yang MD, PhD, Dong In Suh, MD, PhD
Abstract
Leukotriene receptor antagonists (LTRAs) are widely used for asthma and allergic rhinitis (AR), but concerns about the risk of neuropsychiatric events (NPEs) have been raised since the first Drug Safety Communication by the US Food and Drug Administration in 2008. This study evaluates the association between LTRA and NPEs in children, adolescents, and young adults with asthma or AR.
A self-controlled case series study was conducted using the Korean National Health Insurance Service claims database from two three-year observation periods (observation period 1 [Obs1]: 2005 to 2007, observation period 2 [Obs2]: 2016 to 2018). Asthma or AR patients aged 3–30 years who were prescribed LTRAs and diagnosed with NPEs were included. The incidence rate ratios (IRRs) for exposed period and risk periods (1–3, 4–7, 8–14, 15–30, 31–90, >90 days from initiation of LTRA) compared to unexposed periods were calculated using conditional Poisson regression. Subgroup analysis according to age group, type of NPEs and indication of LTRA was performed.
Among 17 001 included patients, the risk of NPEs increased in Obs2 (IRR, 1.11; 95% confidence interval [CI], 1.00–1.22), but did not increase in Obs1. Risk was increased during risk periods 4–7 days (2.36, 1.99–2.76) and 8–14 days (1.78; 1.46–2.15) after initiation of LTRA, particularly in adolescents (1.28, 1.05–1.55) and young adults (1.14, 1.02–1.28), while risk was decreased in children (3–11 years). Risk was not increased for any single type of NPE. AR patients were at increased risk (1.19, 1.01–1.39), but not those with asthma.
Overall, risk of NPEs with LTRA use differed between risk periods and subgroups. Physicians should prescribe LTRAs according to indications and inform patients about possible NPEs.
논문정보
- Research article
- 2022년 05월 (BRIC 등록일 2022-07-26)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
